scholarly journals Meta-analysis of Multiple Myeloma and Benzene Exposure.

2001 ◽  
Vol 11 (6) ◽  
pp. 249-254 ◽  
Author(s):  
Tomoko Sonoda ◽  
Yoshie Nagata ◽  
Mitsuru Mori ◽  
Tadao Ishida ◽  
Kohzoh Imai
Keyword(s):  
Multiple Myeloma ◽  
Meta Analysis ◽  
Benzene Exposure

Renal insufficiency in multiple myeloma: a systematic review and meta-analysis of all randomized trials from 2005–2019

2021 ◽  
pp. 1-13
Author(s):  
Ghulam Rehman Mohyuddin ◽  
Kelly Koehn ◽  
Leyla Shune ◽  
Muhammad Aziz ◽  
Al-Ola Abdallah ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Renal Insufficiency ◽  
Randomized Trials ◽  
Meta Analysis

Food of animal origin and risk of non-Hodgkin lymphoma and multiple myeloma: A review of the literature and meta-analysis

2016 ◽  
Vol 100 ◽  
pp. 16-24 ◽  
Author(s):  
Saverio Caini ◽  
Giovanna Masala ◽  
Patrizia Gnagnarella ◽  
Ilaria Ermini ◽  
William Russell-Edu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
Hodgkin Lymphoma ◽  
Meta Analysis ◽  
Animal Origin ◽  
Review Of The Literature ◽  
Non Hodgkin Lymphoma ◽  
Food Of Animal Origin

Chemotherapy with or without plasmapheresis in acute renal failure due to multiple myeloma: a meta-analysis

2015 ◽  
Vol 53 (05) ◽  
pp. 391-397 ◽  
Author(s):  
Xiaoyong Yu ◽  
Liangying Gan ◽  
Zhaohui Wang ◽  
Bao Dong ◽  
Xiaohong Chen
Keyword(s):  
Multiple Myeloma ◽  
Renal Failure ◽  
Acute Renal Failure ◽  
Meta Analysis

scholarly journals Effect of pomalidomide on relapsed/refractory multiple myeloma: a systematic review and meta-analysis

2017 ◽  
Vol 8 (10) ◽  
pp. 1801-1808 ◽  
Author(s):  
Runzhe Chen ◽  
Yujie Wang ◽  
Chengxin Luan ◽  
Chong Gao ◽  
Xiaoping Zhang ◽  
...  
Keyword(s):  
Systematic Review ◽  
Multiple Myeloma ◽  
Meta Analysis ◽  
Refractory Multiple Myeloma

scholarly journals The VAD Scheme versus Thalidomide plus VAD for Reduction of Vascular Endothelial Growth Factor in Multiple Myeloma: A Meta-Analysis

2018 ◽  
Vol 2018 ◽  
pp. 1-8
Author(s):  
Gan-Lin He ◽  
Duo-Rong Xu ◽  
Wai-Yi Zou ◽  
Sui-Zhi He ◽  
Juan Li
Keyword(s):  
Multiple Myeloma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Meta Analysis ◽  
Biomedical Literature ◽  
Cochrane Library ◽  
Vascular Endothelial ◽  
China National Knowledge Infrastructure ◽  
Significant Difference ◽  
Endothelial Growth Factor

The VAD (vincristine-doxorubicin-dexamethasone) regimen has been used for decades to treat multiple myeloma (MM). Based on reports that vascular endothelial growth factor- (VEGF-) mediated angiogenesis is critical for MM pathogenesis, the antiangiogenic compound thalidomide has been added to VAD (T-VAD). However, it remains unclear whether T-VAD is more efficacious than VAD for serum VEGF reduction or if the difference influences clinical outcome. Pubmed, Cochrane library, China Biomedical Literature (CBM) database, China National Knowledge Infrastructure (CNKI) database, Vip database, and Wanfang database were searched for relevant studies published up to June 2017. RevMan5.2 was used for methodological quality evaluation and data extraction. Thirteen trials (five randomized, seven nonrandomized, and one historically controlled) involving 815 cases were included. Serum VEGF was significantly higher in MM cases than non-MM controls (MD=353.01, [95%CI 187.52–518.51], P<0.01), and the overall efficacy of T-VAD was higher than that of VAD (RR=1.36, [1.21–1.53], P <0.01). Further, T-VAD reduced VEGF to a greater extent than VAD does ([MD=-49.85, [-66.28− -33.42], P<0.01). The T-VAD regimen also reduced VEGF to a greater extent in newly diagnosed MM patients than it did in recurrent patients ([MD=-120.20, [-164.60–-39.80], P<0.01). There was no significant difference in VEGF between T-VAD patients (2 courses) and nontumor controls (MD=175.94, [-26.08–377.95], P=0.09). Greater serum VEGF reduction may be responsible for the superior efficacy of T-VAD compared to VAD.

scholarly journals Efficacy and safety of daratumumab in the treatment of multiple myeloma: a systematic review and meta-analysis

2021 ◽  
Vol 49 (8) ◽  
pp. 030006052110381
Author(s):  
Yin Wang ◽  
Yanqing Li ◽  
Ye Chai
Keyword(s):  
Multiple Myeloma ◽  
Meta Analysis ◽  
Complete Response ◽  
Library Science ◽  
Cochrane Library ◽  
Control Group ◽  
Efficacy And Safety ◽  
Risk Patients ◽  
Grade 3 ◽  
Combination Regimens

Objective To systematically evaluate the efficacy and safety of combination regimens containing daratumumab in patients with multiple myeloma (MM). Methods A systematic search of publications listed on electronic databases (PubMed®, The Cochrane Library, Science Direct and Web of Science) between inception and 13 November 2020 was conducted to find randomized controlled trials (RCTs) that included patients with MM that were treated with combination regimens containing daratumumab. Results A total of seven RCTs were included ( n = 4268 patients). Meta-analysis showed that compared with the control group, the group containing daratumumab showed a significantly better overall response rate and a complete response or better. Daratumumab improved efficacy in both standard-risk and cytogenetically high-risk patients with MM. The prevalence of neutropenia (≥grade 3) and pneumonia was significantly higher in the daratumumab group compared with the control group. Conclusion The available evidence demonstrated that the clinical application of combination regimens containing daratumumab improved the efficacy in patients with MM and had acceptable safety.

Sign in / Sign up

Export Citation Format

Share Document